Clinical Trial Update: A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2a trial of navitoclax (ABT-263) in small cell lung cancer and other non-hematological malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Navitoclax (navitoclax)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Small Cell Lung Cancer, Small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: COMPLETED